Stock News & Analysis

A 64-year streak of increasing the payout makes this a top dividend stock.

Bristol Myers Squibb raised its 2026 sales outlook in July, while Novo Nordisk expects its sales to be flat at best this year, yet Bristol Myers Squibb trades at the lower earnings multiple.

This is one of the highest-quality businesses in the conglomerate's portfolio.

The cloud unit is growing faster than it has in years. Why are the shares cheaper than they were in August?

SpaceX is getting a lot of attention, but Nvidia is still the better buy.

AI's power bottleneck is creating two very different opportunities. See how GE Vernova and Bloom Energy compare in terms of growth, valuation, risk, and ability to power the data center boom.

Elon Musk has two of the largest companies in the world under his management.

This pending purchase could result in both cost savings and supply chain advantages.

Muse is tantalizing investors.

The small coffee shop chain has big ambitions.

Nvidia and Apple generated nearly the same amount of revenue during their most recent quarters.

Interest rates are both a headwind and a tailwind for Ares Capital.

There's a good reason why XRP has never traded higher than a price of $3.84 in more than 14 years.

Nike has struggled to rebuild its brand, and a turnaround won't be quick or easy.

Four of the chipmaker's five previous best years since 1981 were followed by a down year. Why would 2027 be different?

The industry disruptor hasn't been a market-beating investment for its shareholders.

SpaceX is currently valued at roughly $2 trillion.

Palantir's growth is extraordinary, but the valuation sets a demanding bar. See what AIP, margins, government demand, and the math reveal about its long-term upside.

Managing investments may not quite be the business you think it is.

The U.S. government is taking active equity stakes in businesses and is directly shaping capital allocation decisions.